Abstract
Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Current Pharmaceutical Design
Title: Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Giuseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis and Piero Portincasa
Affiliation:
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Abstract: Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Export Options
About this article
Cite this article as:
Giuseppe Palasciano , Antonio Moschetta , Vincenzo O. Palmieri , Ignazio Grattagliano , Gianluca Iacobellis and Piero Portincasa , Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039652
DOI https://dx.doi.org/10.2174/138161207781039652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Effects of Green Tea Catechins: Progress and Promise
Recent Patents on Cardiovascular Drug Discovery Gender Differences in Types, Frequency, Clinical Manifestations and Atherosclerotic Burden of Coronary Artery Anomalies
Reviews on Recent Clinical Trials Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets Dynamic Ventricular Repolarisation: From Physiology to Prognosis
Current Cardiology Reviews Purification and Characterization of a Novel Anti-Proliferative Lectin from Morus alba L. Leaves
Protein & Peptide Letters Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension
Current Pharmaceutical Design Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges
Anti-Cancer Agents in Medicinal Chemistry Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences
Current Pharmaceutical Design Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Current Pharmaceutical Design High Density Lipoprotein Associated Paraoxonase1 Activity in Relation to Oxidative Stress in CAD Patients
Current Cardiology Reviews Thiazide Therapy in Chronic Kidney Disease: Renal and Extra Renal Targets
Current Drug Metabolism Antidiabetic Effect of Spearmint in Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological, Geometric and Biomechanical Factors Influencing Abdominal Aortic Aneurysm Rupture Risk: A Comprehensive Review
Recent Patents on Medical Imaging Preterm Birth and Renin-Angiotensin-Aldosterone System: Evidences of Activation and Impact on Chronic Cardiovascular Disease Risks
Protein & Peptide Letters Critical Illness in Obstetric Patients: Introduction and Epidemiology
Current Women`s Health Reviews Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets 5-HT and NA Reuptake Inhibitors and Appetite Regulation: The Role of the Central 5-HT Network
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)